thalidomide has been researched along with Carcinosarcoma in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Carcinosarcoma: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and adverse events of thalidomide in previously-treated, measurable, persistent or recurrent carcinosarcoma of the uterus, and to explore associations between angiogenic markers with patient demographics and clinical outcome." | 9.16 | A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. ( Abulafia, O; Benbrook, DM; Darcy, KM; Hanjani, P; McMeekin, DS; Pearl, ML; Rose, PG; Rubin, SC; Sill, MW; Small, L, 2012) |
| "To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas." | 9.12 | Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. ( Blank, SV; Christos, P; Fields, AL; Goldberg, GL; Murgo, A; Runowicz, CD; Timmins, P; Wadler, S; Yi-Shin Kuo, D, 2006) |
| "To evaluate the efficacy and adverse events of thalidomide in previously-treated, measurable, persistent or recurrent carcinosarcoma of the uterus, and to explore associations between angiogenic markers with patient demographics and clinical outcome." | 5.16 | A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. ( Abulafia, O; Benbrook, DM; Darcy, KM; Hanjani, P; McMeekin, DS; Pearl, ML; Rose, PG; Rubin, SC; Sill, MW; Small, L, 2012) |
| "To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas." | 5.12 | Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. ( Blank, SV; Christos, P; Fields, AL; Goldberg, GL; Murgo, A; Runowicz, CD; Timmins, P; Wadler, S; Yi-Shin Kuo, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McMeekin, DS | 1 |
| Sill, MW | 1 |
| Darcy, KM | 1 |
| Abulafia, O | 1 |
| Hanjani, P | 1 |
| Pearl, ML | 1 |
| Rubin, SC | 1 |
| Rose, PG | 1 |
| Small, L | 1 |
| Benbrook, DM | 1 |
| Yi-Shin Kuo, D | 1 |
| Timmins, P | 1 |
| Blank, SV | 1 |
| Fields, AL | 1 |
| Goldberg, GL | 1 |
| Murgo, A | 1 |
| Christos, P | 1 |
| Wadler, S | 1 |
| Runowicz, CD | 1 |
2 trials available for thalidomide and Carcinosarcoma
| Article | Year |
|---|---|
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiogenic Proteins; Biomarkers, Tumor; Car | 2012 |
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
Topics: Administration, Oral; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; Neoplasm Recurrence | 2006 |